Search

Search Results

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  542

  PDF: 373

  HTML: 9

• A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

  Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  06-06-2023

  https://doi.org/10.4081/dr.2023.9722

  835

  PDF: 480

  HTML: 25
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1147

  PDF: 570

  HTML: 25

• Papillon-Lefèvre syndrome with excellent response to risankizumab

  Latifah Alibrahim, Sarah Alrashid, Majed Aleissa

  25-02-2026

  https://doi.org/10.4081/dr.2026.10309

  301

  PDF: 296

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1068

  PDF: 568

  SUPPLEMENTARY MATERIAL: 182

  HTML: 21

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1820

  PDF: 723

  HTML: 102

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  973

  PDF: 959

  HTML: 39

• Efficacy of a topical polyphenol-based formulation in palmoplantar psoriasis: an observational study

  Simone Amato, Annunziata Dattola, Luigi Bennardo, Martina Tolone, Steven Paul Nisticò

  08-07-2025

  https://doi.org/10.4081/dr.2025.10333

  505

  PDF: 354

  HTML: 31

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  487

  PDF: 316

  HTML: 23

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  708

  PDF: 448
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1395

  PDF: 769

  HTML: 16